Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, ONTARIO--(Marketwired - April 16, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - April 1, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
IRVINGTON, N.Y., March 30, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven image analysis device intended to provide...
-
TORONTO, ONTARIO--(Marketwired - March 30, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - March 25, 2015) - Spectral Medical Inc., (TSX:EDT)(OTCQX:EDTXQ), a Phase III company developing the first treatment for patients with septic shock guided...
-
TORONTO, ONTARIO--(Marketwired - March 16, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
TORONTO, ONTARIO--(Marketwired - March 10, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for...
-
NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the presentation of new data from the IMPACT...
-
TORONTO, ONTARIO--(Marketwired - Feb. 19, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first therapy for patients...
-
TORONTO, ONTARIO--(Marketwired - Feb. 12, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF) a Phase III company developing the first therapy for patients...